US trade agency extends deadline of Novo Nordisk's historic acquisition

Novo Nordisk has stumbled right before the finish line of the historic acquisition of US-based biotech firm Dicerna. Novo Nordisk has been awarded additional time to get back up by the US Federal Trade Commission (FTC).
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

While shareholders in Dicerna are suing, claiming they received misleading information pertaining to the acquisition of the firm, would-be buyer Novo Nordisk has run into other issues with the US Federal Trade Commission (FTC).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading